The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes
Open accessAbstract
OBJECTIVE: We sought to establish the extent and mechanisms by which sitagliptin and metformin singly and in combination modify islet disease progression in human islet amyloid polypeptide transgenic (HIP) rats, a model for type 2 diabetes. RESEARCH DESIGN AND METHODS: HIP rats were treated with sitagliptin, metformin, sitagliptin plus metformin, or no drug as controls for 12 weeks. Fasting blood glucose, insulin sensitivity, and β-cell mass, function, and turnover were measured in each group. RESULTS: Sitagliptin plus metformin had synergistic effects to preserve β-cell mass in HIP rats. Metformin more than sitagliptin inhibited β-cell apoptosis. Metformin enhanced hepatic insulin sensitivity; sitagliptin enhanced extrahepatic insulin sensitivity with a synergistic effect in combination. β-Cell function was partially preserved by sitagliptin plus metformin. However, sitagliptin treatment was associated with increased pancreatic ductal turnover, ductal metaplasia, and, in one rat, pancreatitis. CONCLUSIONS: The combination of metformin and sitagliptin had synergistic actions to preserve β-cell mass and function and enhance insulin sensitivity in the HIP rat model of type 2 diabetes. However, adverse actions of sitagliptin treatment on exocrine pancreas raise concerns that require further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Glucolipotoxicity: fuel excess and β-cell dysfunction
Poitout, V., & Robertson, R. P. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0023 · Cited by 1,092
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Seltzer, H. S., Allen, E. W., Herron, A. L., & Brennan, M. T. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105534 · Cited by 819 · cited 1×
“In contrast, in those genetically vulnerable to develop type 2 diabetes, -cell function fails to appropriately adapt to insulin resistance, leading to hyperglycemia (3,4).”
BackgroundCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.
Service, G. J., Thompson, G. B., Service, F. J., Andrews, J. C., Collazo-Clavell, M. L., & Lloyd, R. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043690 · Cited by 779
Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113339 · Cited by 763
Meier, J. J., Butler, A. E., Saisho, Y., Monchamp, T., Galasso, R., Bhushan, A., Rizza, R. A., & Butler, P. C. (2008) · Diabetes · doi:10.2337/db07-1369 · Cited by 683
Self-citationAbnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.
Polonsky, K. S., Given, B. D., Hirsch, L. J., Tillil, H., Shapiro, E. T., Beebe, C., Frank, B. H., Galloway, J. A., & Van Cauter, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181903 · Cited by 567
Very Slow Turnover of β-Cells in Aged Adult Mice
Teta, M., Long, S. Y., Wartschow, L. M., Rankin, M. M., & Kushner, J. A. (2005) · Diabetes · doi:10.2337/diabetes.54.9.2557 · Cited by 465
Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Self-citationMannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Meier, J. J., Butler, A. E., Galasso, R., & Butler, P. C. (2006) · Diabetes Care · doi:10.2337/dc06-0392 · Cited by 249
Self-citationGLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
Research works printed but not linked: 39
- King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 · DOI · Paper page
- Xiang, 2006, Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes, Diabetes, 55, 1074, 10.2337/diabetes.55.04.06.db05-1109 · DOI
- Butler, 2003, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes, 52, 102, 10.2337/diabetes.52.1.102 · DOI · Paper page
- Huang, 2007, High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes, Diabetes, 56, 2016, 10.2337/db07-0197 · DOI · Paper page
- Laybutt, 2007, Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes, Diabetologia, 50, 752, 10.1007/s00125-006-0590-z · DOI · Paper page
- Matveyenko, 2006, Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes, Diabetes, 55, 2106, 10.2337/db05-1672 · DOI
- Butler, 2004, Diabetes due to a progressive defectin beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes, Diabetes, 53, 1509, 10.2337/diabetes.53.6.1509 · DOI · Paper page
- Matveyenko, 2009, Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress, Diabetes, 58, 906, 10.2337/db08-1464 · DOI
- Xu, 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
- Buteau, 2001, Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation, Diabetes, 50, 2237, 10.2337/diabetes.50.10.2237 · DOI · Paper page
- Hui, 2003, Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway, Endocrinology, 144, 1444, 10.1210/en.2002-220897 · DOI · Paper page
- Deacon, 2002, Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective, Biochem Biophys Res Commun, 294, 1, 10.1016/S0006-291X(02)00359-5 · DOI
- Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
- Raz, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, 2564, 10.1007/s00125-006-0416-z · DOI · Paper page
- Brazg, 2007, Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes, Diabetes Obes Metab, 9, 186, 10.1111/j.1463-1326.2006.00691.x · DOI
- Cure, 2008, Exenatide and rare adverse events, N Engl J Med, 358, 1969, 10.1056/NEJMc0707137 · DOI
- Matveyenko, 2008, Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein, Am J Physiol Endocrinol Metab, 295, E569, 10.1152/ajpendo.90335.2008 · DOI
- Robertson, 2007, Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient?, Diabetes, 56, 2420, 10.2337/db07-0742 · DOI
- Sakaguchi, 2006, Establishment of animal models for three types of pancreatitis and analyses of regeneration mechanisms, Pancreas, 33, 371, 10.1097/01.mpa.0000236734.39241.99 · DOI
- Emmrich, 1998, Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma, Digestion, 59, 192, 10.1159/000007488 · DOI
- Kloppel, 2007, Chronic pancreatitis, pseudotumors and other tumor-like lesions, Mod Pathol, 20, S113, 10.1038/modpathol.3800690 · DOI · Paper page
- Willemer, 1989, Histochemical and ultrastructural characteristics of tubular complexes in human acute pancreatitis, Dig Dis Sci, 34, 46, 10.1007/BF01536153 · DOI
- Bockman, 1982, Origin of tubular complexes in human chronic pancreatitis, Am J Surg, 144, 243, 10.1016/0002-9610(82)90518-9 · DOI
- Parsa, 1985, Ductal metaplasia of human exocrine pancreas and its association with carcinoma, Cancer Res, 45, 1285
- Marchetti, 2004, Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin, J Clin Endocrinol Metab, 89, 5535, 10.1210/jc.2004-0150 · DOI · Paper page
- Rankin, 2009, Adaptive beta cell proliferation is severely restricted with advanced age, Diabetes, 10.2337/db08-1198 · DOI · Paper page
- Carpenter, 2005, Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery, N Engl J Med, 353, 2192, 10.1056/NEJM200511173532017 · DOI
- Hegen, 1997, Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation, Adv Exp Med Biol, 421, 109, 10.1007/978-1-4757-9613-1_15 · DOI
- Wagner, 2001, A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease, Genes Dev, 15, 286, 10.1101/gad.184701 · DOI · Paper page
- Wagner, 2002, Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells, Gastroenterology, 122, 1898, 10.1053/gast.2002.33594 · DOI
- Lowenfels, 1993, Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group, N Engl J Med, 328, 1433, 10.1056/NEJM199305203282001 · DOI · Paper page
- Eaden, 2001, The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, 48, 526, 10.1136/gut.48.4.526 · DOI · Paper page
- Meisterfeld, 2008, Pancreatic disorders and diabetes mellitus, Exp Clin Endocrinol Diabetes, 116, S7, 10.1055/s-2008-1080918 · DOI
- Everhart, 1995, Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis, JAMA, 273, 1605, 10.1001/jama.1995.03520440059037 · DOI
- Michaud, 2007, Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women, Cancer Epidemiol Biomarkers Prev, 16, 2101, 10.1158/1055-9965.EPI-07-0182 · DOI
- Ishikawa, 1989, Morphologic characteristics of pancreatic carcinoma with diabetes mellitus, Cancer, 64, 1107, 10.1002/1097-0142(19890901)64:5<1107::AID-CNCR2820640523>3.0.CO;2-Y · doi:10.1002/1097-0142(19890901)64:5<1107::aid-cncr2820640523>3.0.co;2-y
- Cuzick, 1989, Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease, Int J Cancer, 43, 415, 10.1002/ijc.2910430312 · DOI · Paper page
- Lankisch, 1982, Exocrine pancreatic function in insulin-dependent diabetes mellitus, Digestion, 25, 211, 10.1159/000198833 · DOI
- Bonner-Weir, 2004, The pancreatic ductal epithelium serves as a potential pool of progenitor cells, Pediatr Diabetes, 5, 16, 10.1111/j.1399-543X.2004.00075.x · DOI · Paper page
Cited by
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Self-citationBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Self-citationAcute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Metadata
- Authors
- Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-29
- Volume
- 58
- Issue
- 7
- Pages
- 1604-1615
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2098008729
- Cited by
- 242
- References
- 19
- FWCI
- 16.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.